Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Sodium Oligomannate in Alzheimer's Disease
NCT05058040Phase 4Active, not recruiting
- Sponsor
- Green Valley
- Start
- Jun 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sodium oligomannate in Alzheimer's disease (AD), sponsored by Green Valley. Started Jun 2021; status: active, not recruiting.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05058040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05058040.